Iterum Therapeutics plc

Spero Therapeutics, Inc.SPRO · BiotechCambridge, United States

68% matchPublic

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Thioredoxin Systems AB is a Swedish biotechnology and pharmaceutical company based in Solna, developing a novel antibiotic regimen to treat multidrug-resistant and complicated urinary tract infections caused by pathogenic bacteria.

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Utility Therapeutics is a biotechnology company focused on developing antibiotics for the treatment of urinary tract infections in the United States. The company developed the FDA-approved product Pivya for uncomplicated urinary tract infections. In 2024, Utility Therapeutics was acquired by Alembic Pharmaceuticals.

TXN SystemsBiotechnologySweden

66% match

TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.